查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012070

肺炎链球菌疫苗市场：2026年至2032年全球市场预测（按疫苗类型、年龄层、分销管道和最终用户划分）

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺炎球菌疫苗市场价值将达到 124.9 亿美元，到 2026 年将成长至 134.5 亿美元，到 2032 年将达到 216.7 亿美元，复合年增长率为 8.18%。

主要市场统计数据
基准年 2025 124.9亿美元
预计年份：2026年 134.5亿美元
预测年份 2032 216.7亿美元
复合年增长率 (%) 8.18%

从策略观点分析近期临床和政策发展对现代肺炎球菌疫苗接种的优先事项和实施挑战的影响。

肺炎链球菌疫苗的现状正处于稳步的科学进步与不断变化的公共卫生优先事项的交汇点。结合疫苗製剂的最新进展、成人和老年族群适应症的扩大，以及对预防侵袭性肺炎链球菌感染的重新重视，都重塑了临床指引和疫苗接种路径。同时，监管机构也不断完善针对高风险族群和季节性免疫策略的建议，促使医疗机构和免疫接种计画重新检视其疫苗接种率政策和工作流程。

产品创新、监管调整和供应链现代化如何重新定义肺炎球菌疫苗的交付和临床决策。

肺炎链球菌疫苗生态系统正经历一场变革，其驱动力包括产品创新、监管改革以及供应链基础设施的日益成熟。新型结合疫苗扩大了血清型覆盖范围，正在改变临床决策，使以往疫苗未能充分涵盖的成人和老年人群获得更广泛的保护。这一演变正促使人们从依赖单一产品转向多种选择，临床医生和保险公司必须根据临床获益、营运可行性和成本效益来评估这些选择。

我们将评估贸易政策变化和关税调整对疫苗供应链、采购韧性和供应连续性的下游营运影响。

近年来，为调整关税制度和贸易立场而实施的政策措施对支撑疫苗生产和分销的医药和医疗供应链产生了切实的影响。进口关税、医疗原料审查程序和执法措施的变化会影响零件、低温运输设备及相关用品的成本基础，进而影响公共和私人免疫项目的筹资策略。当关税波动导致关键原材料的到货成本增加时，製造商和经销商通常会透过优化采购、协商长期供应商合约以及加快对本地生产能力的投资来应对。

以细分为主导的框架，将疫苗类型、年龄组优先事项、通路和医疗保健环境之间的差异与营运和临床决策联繫起来。

精细的市场细分观点阐明了产品特性、患者群体特征、通路和医疗机构如何影响需求模式和专案优先事项。根据疫苗类型，对结合疫苗和多醣体疫苗的情况进行评估。结合疫苗也根据特定配方进行区分，例如PCV13、PCV15和PCV20。这些差异会影响临床建议、预期免疫抗原性和低温运输处理要求。根据年龄，针对成人、儿童和老年族群制定相应的临床和计画策略，并考虑不同族群的易感性、合併症情况和建议的接种程序。

区域趋势使全球主要区域内不同的医疗保健基础设施、政策环境和交付重点保持一致，并制定相应的部署策略。

区域趋势持续影响肺炎球菌疫苗在不同医疗体系中的引入、优先排序和资金筹措方式。在美洲，免疫规划通常着重于涵盖弱势群体，同时兼顾健全的公共免疫基础设施与多元化的支付体系。区域筹资策略、国家免疫规划和公共卫生宣传活动都会影响疫苗接种率和规划设计，因此，製造商和卫生部门需要合作解决覆盖率差异问题。

製药公司采取的策略性措施着重于高价配方、生产韧性和证据生成，以维持其临床和商业性意义。

肺炎链球菌疫苗领域的竞争格局呈现出传统製剂与新一代製剂并存的局面，各公司致力于生命週期管理、拓展适应症以及收集上市后证据以维持其临床意义。主要企业的策略重点包括加速开发高通量结合疫苗、加强成人适应症的监管文件以及扩大製造地以提高供应可靠性。加速产品上市并解决无菌生产瓶颈的常见策略包括与契约製造生产商合作以及投资填充和包装能力。

采取切实可行的措施，将临床价值和供应弹性、相关人员合作以及有针对性的获取策略相结合，以提高疫苗计划的有效性。

产业领导者应优先采取一系列连贯的行动，以兼顾临床价值、供应韧性和公平取得。首先，整合产品系列决策和营运能力，确保筹资策略能反映不同配方需求、低温运输需求和给药方案的差异。这种协调有助于减少营运摩擦，并支援在各种医疗环境中实现稳定的供应。其次，投资于联合供应协议和能力建设倡议，以加强区域填充和包装能力，从而降低进口相关波动风险，并确保及时供应。

透过采用混合方法，整合临床证据、专家意见和营运审查，我们为利害关係人产生可操作且检验的见解。

本分析的调查方法结合了系统性文献综述、针对性专家访谈和供应链审查，以确保证据基础的稳健性和透明度。同行评审的临床研究、监管指导文件和公开的安全监测报告构成了评估临床疗效、适应症和核准后表现的基础。来自临床医生、疫苗学家、供应链专家和卫生政策顾问的专家见解，阐明了证据如何在医疗保健机构的营运和采购决策中得到体现。

综合结论将科学进步、监管变革和营运韧性与改善免疫接种效果的实用建议联繫起来。

总而言之，肺炎球菌疫苗领域正从多个方面演变，包括结合製剂的科学创新、政策和指南趋势的转变，以及对供应链稳健性的日益重视。这些因素迫使相关人员重新思考产品选择、筹资策略和交付模式，以确保临床进展能够转化为对所有年龄层和医疗机构的更广泛保护。有效的因应措施需要全面规划，涵盖与监管环境的协调、生产韧性以及针对高风险族群的有针对性的宣传活动。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肺炎链球菌疫苗市场：依疫苗类型划分

  • 结合疫苗
    • PCV13
    • PCV15
    • PCV20
  • 多醣体疫苗

第九章：肺炎链球菌疫苗市场：依年龄组别划分

  • 成人版
  • 儿童
  • 老年人

第十章 肺炎链球菌疫苗市场：依通路划分

  • 离线
  • 在线的

第十一章 肺炎链球菌疫苗市场：依最终用户划分

  • 门诊部
  • 诊所
  • 医院
  • 疫苗接种中心

第十二章 肺炎链球菌疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肺炎链球菌疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 肺炎链球菌疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国肺炎链球菌疫苗市场

第十六章：中国肺炎链球菌疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott
  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • BioNTech SE
  • GSK plc
  • Inventprise LLC
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK Bioscience Co., Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market was valued at USD 12.49 billion in 2025 and is projected to grow to USD 13.45 billion in 2026, with a CAGR of 8.18%, reaching USD 21.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.49 billion
Estimated Year [2026] USD 13.45 billion
Forecast Year [2032] USD 21.67 billion
CAGR (%) 8.18%

A strategic orientation to recent clinical and policy advances that frame contemporary pneumococcal vaccination priorities and implementation imperatives

The pneumococcal vaccine landscape sits at the intersection of robust scientific advancement and evolving public health priorities. Recent developments in conjugate vaccine formulations, expanded licensure across adult and geriatric populations, and a renewed emphasis on preventing invasive pneumococcal disease have reshaped clinical guidelines and vaccination pathways. At the same time, regulatory bodies continue to refine recommendations for high-risk groups and seasonal immunization strategies, prompting healthcare providers and immunization programs to revisit coverage policies and operational workflows.

Across clinical and operational domains, two parallel dynamics are evident: the refinement of vaccine composition to broaden serotype coverage and a strategic push to improve equitable access through supply chain optimization and provider education. These dynamics are accompanied by intensified collaboration among manufacturers, public health agencies, and clinical societies to ensure alignment on indications, administration schedules, and post-marketing surveillance. As a result, stakeholders from procurement to point-of-care are recalibrating clinical protocols and supply arrangements to reflect both the scientific advances and the logistical realities of vaccine delivery.

For decision-makers, a clear understanding of recent clinical data, policy updates, and delivery constraints is essential. Integrating these elements supports coherent strategies for immunization program design, formulary decisions, and outreach to populations with elevated risk, thereby ensuring that clinical gains translate into measurable public health impact.

How product innovation, regulatory adaptation, and supply chain modernization are collectively redefining pneumococcal vaccine delivery and clinical decision-making

The pneumococcal vaccine ecosystem is undergoing transformative shifts driven by product innovation, regulatory recalibration, and the maturation of delivery infrastructures. Newer conjugate formulations expanding serotype coverage have altered clinical decision-making, facilitating broader protection for adults and older populations previously underserved by earlier vaccine generations. This evolution is reinforcing a transition from single-product reliance toward a diversified set of options that clinicians and payers must evaluate on the basis of clinical benefit, operational feasibility, and cost-effectiveness.

Meanwhile, regulatory pathways and advisory committee guidance are adapting to emerging evidence, creating both opportunities and operational challenges for immunization programs. Manufacturers are responding with lifecycle strategies that emphasize post-approval evidence and engagement with health authorities to secure label expansions. At the same time, distribution networks and cold chain logistics are becoming more sophisticated, integrating digital visibility tools and regional partnerships to reduce wastage and improve reach into under-immunized communities.

These shifts collectively encourage stakeholders to prioritize agile procurement, enhanced surveillance, and targeted provider education. By aligning supply strategies with clinical guidance, health systems can accelerate uptake where the public health benefit is greatest while managing the logistical complexity introduced by a broader product mix and evolving immunization schedules.

Assessing the downstream operational consequences of altered trade policies and tariff adjustments on vaccine supply chains, procurement resilience, and delivery continuity

Policy measures enacted in recent years to adjust tariff regimes and trade posture have had tangible implications for the pharmaceutical and medical supply chains that support vaccine production and distribution. Changes to import duties, review protocols for medical inputs, and enforcement practices can influence the cost base for components, cold chain equipment, and ancillary supplies, which in turn affects procurement strategies for public and private immunization programs. Where tariff shifts increase landed costs for critical inputs, manufacturers and distributors often respond by optimizing sourcing, negotiating longer-term supplier agreements, and accelerating investments in local manufacturing capabilities.

In the context of pneumococcal vaccines, the cumulative effect of tariff adjustments necessitates careful scrutiny of supply chains that span raw antigen procurement, vial and syringe suppliers, and temperature-controlled logistics providers. Health systems and manufacturers are increasingly focusing on supply diversification and onshoring initiatives to mitigate exposure to import-related cost volatility. Concurrently, procurement officers are placing greater emphasis on contractual terms that lock in supply commitments and clarify responsibility for customs-related delays.

As a result, organizations involved in vaccine delivery are revising procurement frameworks, budgeting assumptions for cold chain capacity, and contingency planning to ensure continuity of vaccination services. These adaptations underscore the importance of integrated supply chain risk management that accounts for trade policy dynamics alongside clinical and operational considerations.

A segmentation-driven framework linking vaccine type differentiation, age-specific priorities, distribution channels, and care settings to operational and clinical decision-making

A nuanced segmentation lens clarifies how product characteristics, patient demographics, distribution pathways, and care settings shape demand patterns and program priorities. Based on Vaccine Type, the landscape is evaluated across Conjugate Vaccine and Polysaccharide Vaccine, with conjugate options further differentiated by specific formulations including Pcv13, Pcv15, and Pcv20; these distinctions influence clinical recommendations, immunogenicity expectations, and cold chain handling requirements. Based on Age Group, clinical and program strategies are tailored for Adult, Children, and Geriatric cohorts given differences in susceptibility, comorbidity profiles, and recommended administration schedules.

Based on Distribution Channel, distribution dynamics vary between Offline and Online pathways, with traditional provider-administered channels remaining central to routine immunization while digital procurement and telehealth-enabled coordination are expanding access and convenience. Based on End User, program design and logistics are shaped by site-specific needs across Ambulatory Care Centers, Clinics, Hospitals, and Immunization Centers, each of which has distinct staffing models, cold storage capacity, and patient throughput patterns. Integrating these segmentation dimensions enables stakeholders to align product selection, education efforts, and logistics investments with the practical realities of each setting and population cohort.

This segmentation-driven approach facilitates targeted interventions, such as prioritizing high-valency conjugate formulations in settings serving older adults or optimizing online ordering workflows for smaller clinics, thereby improving alignment between clinical value and operational delivery.

Regional dynamics and tailored deployment strategies that reconcile diverse healthcare infrastructures, policy landscapes, and delivery priorities across major global regions

Regional dynamics continue to shape how pneumococcal vaccines are introduced, prioritized, and financed across diverse healthcare ecosystems. In the Americas, vaccination programs often balance strong public immunization infrastructure with varied payer arrangements and concentrated efforts to reach marginalized populations. Regional procurement strategies, national immunization schedules, and public health campaigns influence both uptake and program design, prompting collaboration between manufacturers and health authorities to address coverage gaps.

In Europe, Middle East & Africa, the environment is heterogeneous, with high-income health systems focusing on guideline alignment and adult immunization, while low- and middle-income settings prioritize pediatric access and cold chain expansion. Policy heterogeneity across this combined region underscores the need for adaptive distribution strategies and targeted support for regulatory harmonization and capacity building. In the Asia-Pacific region, rapid urbanization, expanding private healthcare delivery, and substantial investments in domestic manufacturing capacity are reshaping access models. Regional stakeholders are leveraging technology-enabled ordering, decentralized cold chain solutions, and partnerships to increase reach in both urban and rural settings.

Across these regions, manufacturers and public health entities must calibrate launch strategies, supply allocation, and educational outreach to reflect local regulatory processes, healthcare delivery models, and population health priorities. Such regional tailoring increases the effectiveness of immunization efforts and facilitates more efficient use of available resources.

Strategic manufacturer initiatives focusing on higher-valency formulations, manufacturing resilience, and evidence-generation to sustain clinical and commercial relevance

The competitive landscape in the pneumococcal vaccine field is characterized by a mix of legacy products and next-generation formulations, with companies focusing on lifecycle management, label expansions, and post-marketing evidence generation to sustain clinical relevance. Strategic priorities among leading manufacturers include advancing higher-valency conjugate options, strengthening regulatory dossiers for adult indications, and expanding manufacturing footprint to enhance supply reliability. Partnerships with contract manufacturers and investments in fill-and-finish capacity are common tactics to accelerate market readiness and reduce bottlenecks associated with sterile manufacturing.

In parallel, manufacturers are investing in real-world evidence programs and pharmacovigilance initiatives to support clinicians and payers in assessing comparative effectiveness and safety across populations. Engagement with advisory bodies and professional societies is central to shaping guideline updates and bolstering clinician confidence in new formulations. Commercial strategies increasingly emphasize value-based propositions that link clinical benefits with operational advantages such as reduced dosing complexity or improved stability at standard refrigeration temperatures.

For purchasers and health systems, understanding each company's manufacturing resilience, evidence-generation plans, and distribution partnerships is essential when assessing supply options. This insight helps inform procurement discussions, risk-sharing arrangements, and collaborative initiatives to expand access while maintaining consistent delivery performance.

Actionable measures for integrating clinical value with supply resilience, stakeholder engagement, and targeted access strategies to enhance vaccine program effectiveness

Industry leaders should prioritize a coherent set of actions that align clinical value, supply resilience, and equitable access. First, integrate product portfolio decisions with operational capabilities by ensuring that procurement strategies reflect differences in formulation requirements, cold chain needs, and administration schedules. This alignment reduces operational friction and supports consistent delivery across diverse care settings. Next, invest in collaborative supply agreements and capacity-building initiatives that reduce exposure to import-related volatility and strengthen regional fill-and-finish capabilities to support timely availability.

Additionally, elevate evidence synthesis and provider engagement efforts to accelerate appropriate uptake. Real-world safety and effectiveness data should be systematically collected and translated into concise clinical tools and decision aids for frontline clinicians. Strengthening partnerships with public health agencies and professional societies will facilitate guideline alignment and improve the clarity of risk-based recommendations. From a commercial perspective, consider structured contracting approaches that include performance clauses and supply continuity commitments, which can mitigate disruption risk and align incentives across stakeholders.

Finally, develop targeted outreach strategies for populations with lower uptake, leveraging digital platforms for appointment scheduling and vaccine reminders while reinforcing in-person access through community immunization centers. These combined steps will help organizations convert scientific advances into measurable improvements in population protection and program efficiency.

A mixed-methods research approach synthesizing clinical evidence, expert input, and operational review to produce actionable and validated insights for stakeholders

The research methodology underpinning this analysis combines systematic literature appraisal, targeted expert interviews, and supply chain review to ensure a robust and transparent evidence base. Peer-reviewed clinical studies, regulatory guidance documents, and publicly available safety surveillance reports formed the foundation for assessing clinical efficacy, indications, and post-authorization experience. Expert input was obtained from clinicians, vaccinologists, supply chain specialists, and health policy advisors to contextualize how evidence translates into operational and procurement decisions across care settings.

Operational insights were developed through examination of distribution channel dynamics, cold chain infrastructure reports, and procurement practice analyses, complemented by engagement with logistics providers and vaccination program managers to validate practical constraints and feasible solutions. Regulatory timelines and label expansions were reviewed to understand how product availability and indication alignment influence clinical practice. Where appropriate, triangulation of data sources and cross-validation with subject matter experts were used to resolve discrepancies and ensure analytical rigor.

This mixed-methods approach balances empirical evidence with practitioner expertise, producing actionable insights that reflect both scientific validity and the pragmatic realities of vaccine delivery and program implementation.

Integrated conclusions linking scientific advancement, regulatory evolution, and operational resilience to practical recommendations for advancing immunization outcomes

In summary, the pneumococcal vaccine environment is advancing along multiple dimensions: scientific innovation in conjugate formulations, evolving policy and guideline landscapes, and a growing emphasis on supply chain robustness. These forces are prompting stakeholders to rethink product selection, procurement strategies, and delivery models to ensure that clinical advances translate into expanded protection across age groups and care settings. Effective responses require integrated planning that spans regulatory engagement, manufacturing resilience, and targeted outreach to populations at elevated risk.

Moving from insight to action involves aligning evidence-generation with operational execution. Strengthened surveillance and real-world data programs, combined with strategic contracting and local capacity investments, can mitigate disruption risk and enhance access. At the clinical interface, continued education and clear guideline communication will be essential to harmonize practice patterns and optimize vaccine utilization across adult, pediatric, and geriatric populations. Ultimately, stakeholders that proactively coordinate clinical, commercial, and logistical strategies will be best positioned to convert recent innovations into sustained public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
    • 8.1.1. Pcv13
    • 8.1.2. Pcv15
    • 8.1.3. Pcv20
  • 8.2. Polysaccharide Vaccine

9. Pneumococcal Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Children
  • 9.3. Geriatric

10. Pneumococcal Vaccine Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Pneumococcal Vaccine Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Immunization Centers

12. Pneumococcal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pneumococcal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pneumococcal Vaccine Market

16. China Pneumococcal Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott
  • 17.6. Astellas Pharma Inc.
  • 17.7. Beijing Minhai Biotechnology Co., Ltd.
  • 17.8. Bharat Biotech International Ltd.
  • 17.9. Biological E. Limited
  • 17.10. BioNTech SE
  • 17.11. GSK plc
  • 17.12. Inventprise LLC
  • 17.13. KM Biologics Co., Ltd.
  • 17.14. LG Chem Ltd.
  • 17.15. Merck & Co., Inc.
  • 17.16. Novartis AG
  • 17.17. Panacea Biotec Ltd.
  • 17.18. Pfizer Inc.
  • 17.19. Pnuvax Incorporated
  • 17.20. Sanofi S.A.
  • 17.21. Serum Institute of India Pvt. Ltd.
  • 17.22. Shenzhen Kangtai Biological Products Co., Ltd.
  • 17.23. SK Bioscience Co., Ltd.
  • 17.24. Vaxcyte Inc.
  • 17.25. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)